FCGR2A and autoimmune thrombocytopenic purpura: However, there is no clear consensus on the optimal sequence of medications, leading to heterogeneity in the treatment of relapsed ITP.27Due to the side effects of long-term corticosteroid use and the difficulty in maintaining the efficacy of IVIg, many patients prefer using TPO-RA, rituximab, Syk inhibitors, and Fcγ receptor (FcγR) inhibitors when the disease recurs.28Approximately 80% of patients with persistent or chronic recurrent ITP use TPO-RA drugs, 76% choose rituximab, and 55% choose other types of immunosuppressants.